Trial Profile
A National, Multi Center, Randomized, Open-label, Phase II Trial of Tarceva Versus Combination of Gemcitabine Plus Cisplatin as Neoadjuvant Treatment in Stage IIIA-N1,N2 NSCLC With Activating EGFR Mutation in Exon 19 or 21
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
- 02 Jun 2015 Interim results (n=39;till Jan 15,2015 ) till presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 15 Feb 2011 New trial record